{"id":"W2734872002","doi":"10.1200/jco.2017.35.15_suppl.tps3101","title":"A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; Tolerability; CD47; Immune checkpoint; Blockade; Immune system; Cancer research; Immunology; Internal medicine; Receptor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004589718,0.0002589859,0.002070623,0.0002398791,0.0002216387,0.00004575965,0.0003931813,0.000707745,0.0001004559],"category_scores_gemma":[0.006411554,0.000175093,0.0003126857,0.0001252096,0.0006833434,0.0006453425,0.0001506773,0.001323137,0.000003873226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001488615,"about_ca_system_score_gemma":0.001296865,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001250932,"about_ca_topic_score_gemma":0.0001173698,"domain_scores_codex":[0.9946803,0.0006491287,0.003827045,0.000324055,0.000135728,0.0003836766],"domain_scores_gemma":[0.9914117,0.001560212,0.006212158,0.0003560137,0.0003643038,0.00009563872],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.232888,0.006188991,0.003438204,0.00005585014,0.0003421927,0.000212793,0.0004099396,0.00001849827,0.7077476,0.00002930061,0.0001551297,0.04851355],"study_design_scores_gemma":[0.4850526,0.1183365,0.2659968,0.0014999,0.0006152327,0.002142792,0.0009884764,0.000448744,0.1189445,0.0001687178,0.00506484,0.0007409098],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952863,0.001005508,0.00007422197,0.0006685604,0.00232256,0.0004048084,0.000008571921,0.000009833439,0.0002196058],"genre_scores_gemma":[0.9978312,0.000579615,0.0009552684,0.0000558853,0.0004096313,0.000009917782,0.0000147767,0.00002606666,0.0001176739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5888031,"threshold_uncertainty_score":0.7675692,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08247291652155142,"score_gpt":0.4128003983709206,"score_spread":0.3303274818493692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}